Literature DB >> 22768019

Inflammasomes and Intestinal Tumorigenesis.

Md Hasan Zaki1, Mohamed Lamkanfi, Thirumala-Devi Kanneganti.   

Abstract

Colorectal cancer is a major health problem in developed countries. Chronic intestinal inflammation predisposes individuals to the development of colorectal cancer. The intracellular NOD-like receptors (NLRs) have emerged as crucial regulators of intestinal inflammation and colorectal tumorigenesis. Activation of several NLRs leads to the formation of a protein complex called the inflammasome, which then triggers the activation of the cysteine protease caspase-1 and the downstream maturation and secretion of the inflammatory cytokines interleukin-1β and -18. Defective inflammasome signaling in the gut contributes to colitis and colorectal tumorigenesis by increasing the permeability of the epithelial barrier, dysregulating the proliferation of epithelial cells, and inducing oncogenic mediators. In this review, we discuss our current knowledge on how the inflammasome protects against colorectal tumorigenesis.

Entities:  

Year:  2011        PMID: 22768019      PMCID: PMC3388509          DOI: 10.1016/j.ddmec.2011.11.003

Source DB:  PubMed          Journal:  Drug Discov Today Dis Mech        ISSN: 1740-6765


  48 in total

Review 1.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

Review 2.  Intracellular NOD-like receptors in host defense and disease.

Authors:  Thirumala-Devi Kanneganti; Mohamed Lamkanfi; Gabriel Núñez
Journal:  Immunity       Date:  2007-10       Impact factor: 31.745

3.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis.

Authors:  J A Eaden; K R Abrams; J F Mayberry
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

4.  Potent antitumor effects mediated by local expression of the mature form of the interferon-gamma inducing factor, interleukin-18 (IL-18).

Authors:  T Osaki; W Hashimoto; A Gambotto; H Okamura; P D Robbins; M Kurimoto; M T Lotze; H Tahara
Journal:  Gene Ther       Date:  1999-05       Impact factor: 5.250

5.  Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production.

Authors:  B Siegmund; G Fantuzzi; F Rieder; F Gamboni-Robertson; H A Lehr; G Hartmann; C A Dinarello; S Endres; A Eigler
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2001-10       Impact factor: 3.619

6.  Nitric oxide synthase inhibitor and IL-18 enhance the anti-tumor immune response of rats carrying an intrahepatic colon carcinoma.

Authors:  P Hegardt; B Widegren; L Li; B Sjögren; C Kjellman; I Sur; H O Sjögren
Journal:  Cancer Immunol Immunother       Date:  2001-11       Impact factor: 6.968

7.  Innate immune detection of the type III secretion apparatus through the NLRC4 inflammasome.

Authors:  Edward A Miao; Dat P Mao; Natalya Yudkovsky; Richard Bonneau; Cynthia G Lorang; Sarah E Warren; Irina A Leaf; Alan Aderem
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-01       Impact factor: 11.205

Review 8.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.

Authors:  J E Darnell; I M Kerr; G R Stark
Journal:  Science       Date:  1994-06-03       Impact factor: 47.728

9.  The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses.

Authors:  Vijay A K Rathinam; Zhaozhao Jiang; Stephen N Waggoner; Shruti Sharma; Leah E Cole; Lisa Waggoner; Sivapriya Kailasan Vanaja; Brian G Monks; Sandhya Ganesan; Eicke Latz; Veit Hornung; Stefanie N Vogel; Eva Szomolanyi-Tsuda; Katherine A Fitzgerald
Journal:  Nat Immunol       Date:  2010-03-28       Impact factor: 25.606

Review 10.  Inflammasomes: guardians of cytosolic sanctity.

Authors:  Mohamed Lamkanfi; Vishva M Dixit
Journal:  Immunol Rev       Date:  2009-01       Impact factor: 12.988

View more
  6 in total

1.  Defective Intestinal Mucin-Type O-Glycosylation Causes Spontaneous Colitis-Associated Cancer in Mice.

Authors:  Kirk Bergstrom; Xiaowei Liu; Yiming Zhao; Nan Gao; Qian Wu; Kai Song; Yi Cui; Yun Li; J Michael McDaniel; Samuel McGee; Weichang Chen; Mark M Huycke; Courtney W Houchen; Lauren A Zenewicz; Christopher M West; Hong Chen; Jonathan Braun; Jianxin Fu; Lijun Xia
Journal:  Gastroenterology       Date:  2016-04-06       Impact factor: 22.682

2.  PTPN2 Regulates Inflammasome Activation and Controls Onset of Intestinal Inflammation and Colon Cancer.

Authors:  Marianne R Spalinger; Roberto Manzini; Larissa Hering; Julianne B Riggs; Claudia Gottier; Silvia Lang; Kirstin Atrott; Antonia Fettelschoss; Florian Olomski; Thomas M Kündig; Michael Fried; Declan F McCole; Gerhard Rogler; Michael Scharl
Journal:  Cell Rep       Date:  2018-02-13       Impact factor: 9.423

Review 3.  Inflammasome as a Therapeutic Target for Cancer Prevention and Treatment.

Authors:  Huyen Trang Ha Thi; Suntaek Hong
Journal:  J Cancer Prev       Date:  2017-06-30

Review 4.  Inflammasomes in Inflammation-Induced Cancer.

Authors:  Chu Lin; Jun Zhang
Journal:  Front Immunol       Date:  2017-03-15       Impact factor: 7.561

Review 5.  Learning on the Fly: The Interplay between Caspases and Cancer.

Authors:  Derek Cui Xu; Lewis Arthurton; Luis Alberto Baena-Lopez
Journal:  Biomed Res Int       Date:  2018-04-29       Impact factor: 3.411

Review 6.  Crosstalk between NLRP12 and JNK during Hepatocellular Carcinoma.

Authors:  Shahanshah Khan; Hasan Zaki
Journal:  Int J Mol Sci       Date:  2020-01-13       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.